Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.495 USD | +3.10% | +14.73% | -6.92% |
May. 01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
Mar. 18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 1.7M | Sales 2025 * | 2.11M | Capitalization | 41.64M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -23M | EV / Sales 2024 * | 24.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 19.8 x |
P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-2.35
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.52% |
1 day | +2.41% | ||
1 week | +14.73% | ||
Current month | +1.37% | ||
1 month | +1.37% | ||
3 months | -21.28% | ||
6 months | +54.18% | ||
Current year | -6.92% |
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Joshua M. Fine
DFI | Director of Finance/CFO | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
William Shanahan
BRD | Director/Board Member | 84 | 16-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1.48 | +2.07% | 17 039 |
24-05-01 | 1.45 | -0.68% | 29,137 |
24-04-30 | 1.46 | -0.68% | 32,673 |
24-04-29 | 1.47 | +16.67% | 56,557 |
24-04-26 | 1.26 | -2.33% | 28,155 |
Delayed Quote Nasdaq, May 02, 2024 at 03:36 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.92% | 41.64M | |
+29.98% | 699B | |
+25.07% | 571B | |
-4.67% | 364B | |
+17.98% | 326B | |
+3.65% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.77% | 154B |
- Stock Market
- Equities
- CYTH Stock